Occlutech PDA Occluder​

Occlutech PDA Occluder​

Occlutech provides both regular shank and long shank PDA occluders to address different types of defects.

  • Regular Shank: Suitable for Type A defects.
  • Long Shank: Allows easy closure of Type E defects.

Key Features and Benefits

  • Universal Ball Connector Mechanism: Ensures safer device release and greater flexibility in implanting the occluder from various angles.
  • Longer Ball Length (2 mm): Facilitates easy recapture if needed.
  • Hubless Design: Prevents pulmonary obstruction in young children.

Advantages

The Occlutech PDA Occluder offers several significant advantages:

  • Superior Flexibility and Adaptability
  • Corrosion Resistance: Reduced nickel leaching.
  • Quick Sealing: Prevents aortic obstruction.
  • Lower Thrombus Risk
  • No Hub in Aortic Disk: Allows easy recapture.
  • Excellent Anchoring and Stability

Clinical Design and Efficacy

  • Radiopacity: Ensures proper placement with angiographic equipment.
  • Pre-sized Design: The device remains stable within the duct due to pulmonary anchoring, preventing aortic protrusion and accommodating hypertensive pulmonary ducts.

Occlutech PDA Occluder Specifications

Occlutech provides a range of sizes for both regular and hubless PDA occluders to ensure optimal fit and performance:

  • Regular Shank PDA Occluder:
  • 42PDA05/92PDA05: Ø D1 = 9 mm, Ø D2 = 3.5 mm, Ø D3 = 5 mm, Length L = 4.25 mm, Delivery Set = 6F
  • 42PDA06/92PDA05: Ø D1 = 10 mm, Ø D2 = 4 mm, Ø D3 = 6 mm, Length L = 5 mm, Delivery Set = 6F
  • Long Shank PDA Occluder:
  • 43PDA05L/93PDA05L: Ø D1 = 9 mm, Ø D2 = 3.5 mm, Ø D3 = 5 mm, Length L = 7 mm, Delivery Set = 6F
  • 43PDA06L/93PDA06L: Ø D1 = 10 mm, Ø D2 = 4 mm, Ø D3 = 6 mm, Length L = 7.5 mm, Delivery Set = 6F

Patent Ductus Arteriosus (PDA) is a congenital heart defect characterized by the persistence of the ductus arteriosus, a vessel that connects the pulmonary artery to the descending aorta, which normally closes shortly after birth. PDAs represent 5% to 10% of all congenital heart defects. The overall incidence of symptomatic PDA is 1 in 2000, while the total incidence, including “silent” PDAs, can reach up to 1 in 500. Approximately 5,200 new symptomatic PDA cases are diagnosed annually in the United States, Europe, and Japan, with around 40,000 interventions performed each year, predominantly in developing countries.

Types of PDA

PDAs occur with various morphologies, which can influence the choice of treatment. Occlutech offers two different designs with different attachment mechanisms to accommodate these variations.